EP1435989A4 - Ptp1b inhibitors and ligands - Google Patents

Ptp1b inhibitors and ligands

Info

Publication number
EP1435989A4
EP1435989A4 EP02803148A EP02803148A EP1435989A4 EP 1435989 A4 EP1435989 A4 EP 1435989A4 EP 02803148 A EP02803148 A EP 02803148A EP 02803148 A EP02803148 A EP 02803148A EP 1435989 A4 EP1435989 A4 EP 1435989A4
Authority
EP
European Patent Office
Prior art keywords
ligands
ptp1b inhibitors
ptp1b
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02803148A
Other languages
German (de)
French (fr)
Other versions
EP1435989A1 (en
Inventor
Zhong-Yin Zhang
David S Lawrence
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Original Assignee
Albert Einstein College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine filed Critical Albert Einstein College of Medicine
Publication of EP1435989A1 publication Critical patent/EP1435989A1/en
Publication of EP1435989A4 publication Critical patent/EP1435989A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
EP02803148A 2001-09-26 2002-09-26 Ptp1b inhibitors and ligands Withdrawn EP1435989A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32500901P 2001-09-26 2001-09-26
US325009P 2001-09-26
PCT/US2002/030492 WO2003041729A1 (en) 2001-09-26 2002-09-26 Ptp1b inhibitors and ligands

Publications (2)

Publication Number Publication Date
EP1435989A1 EP1435989A1 (en) 2004-07-14
EP1435989A4 true EP1435989A4 (en) 2006-05-03

Family

ID=23266058

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02803148A Withdrawn EP1435989A4 (en) 2001-09-26 2002-09-26 Ptp1b inhibitors and ligands

Country Status (6)

Country Link
US (1) US20040191926A1 (en)
EP (1) EP1435989A4 (en)
JP (1) JP2005509008A (en)
AU (1) AU2002363632B2 (en)
CA (1) CA2461481A1 (en)
WO (1) WO2003041729A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002479A1 (en) * 2002-03-12 2004-01-01 Yihan Wang Peptide analogues and uses thereof
US7759459B2 (en) * 2003-01-10 2010-07-20 Albert Einstein College Of Medicine Of Yeshiva University Fluorescent assays for protein kinases
WO2005079300A2 (en) 2004-02-13 2005-09-01 Albert Einstein College Of Medicine Of Yeshiva University Protein kinase inhibitors and methods for identifying same
US7521473B2 (en) 2004-02-25 2009-04-21 Wyeth Inhibitors of protein tyrosine phosphatase 1B
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc Method of treating men with metabolic and anthropometric disorders
US7736911B2 (en) * 2004-04-15 2010-06-15 Albert Einstein College Of Medicine Of Yeshiva University Activity-based probes for protein tyrosine phosphatases
EP1765332A2 (en) * 2004-06-17 2007-03-28 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
JP2008505916A (en) * 2004-07-09 2008-02-28 メタバシス・セラピューティクス・インコーポレイテッド Oxygen / nitrogen heterocycle inhibitors of tyrosine phosphatase
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
EP1812012A4 (en) 2004-11-15 2010-02-17 Ceptyr Inc Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2007028145A2 (en) * 2005-09-02 2007-03-08 Dara Biosciences, Inc. Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8399213B2 (en) * 2008-09-30 2013-03-19 University Of Southern California Method for monitoring intracellular tyrosine phosphatase activity
US20100317831A1 (en) * 2009-06-14 2010-12-16 National Taiwan University Probe compounds for protein tyrosine phosphatase (ptp) and precursors thereof
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
JP6442412B2 (en) 2013-03-15 2018-12-19 持田製薬株式会社 Compositions and methods for the treatment of non-alcoholic steatohepatitis
JP2016514670A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase receptor agonists in combination with other drugs
RS65632B1 (en) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-pure agonists of guanylate cyclase c, method of making and using same
AU2015320748A1 (en) * 2014-09-25 2017-04-20 Cold Spring Harbor Laboratory Treatment of Rett Syndrome

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008600A1 (en) * 1992-10-09 1994-04-28 Joslin Diabetes Center Inhibition of signal transduction molecules
WO2003093498A1 (en) * 2002-04-29 2003-11-13 The Ohio State University Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US621487A (en) * 1899-03-21 Joseph b
US5326905A (en) * 1990-04-02 1994-07-05 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US5763577A (en) * 1993-10-25 1998-06-09 Warner-Lambert Company Substituted tetra- and pentapeptide inhibitors of protein: farnesyl transferase
US5714361A (en) * 1994-02-14 1998-02-03 Indiana University Foundation Phosphatase/phosphodiesterase enzyme inhibitors and methods
US5580979A (en) * 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
DE69632821T2 (en) * 1995-04-25 2005-08-25 Daiichi Fine Chemical Co., Ltd., Takaoka HIGHLY METALOPROTEINASE INHIBITOR IN WATER
US5860127A (en) * 1995-06-01 1999-01-12 Hitachi, Ltd. Cache memory employing dynamically controlled data array start timing and a microcomputer using the same
US5770620A (en) * 1995-06-19 1998-06-23 Ontogen Corporation Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
GB9603227D0 (en) * 1996-02-15 1996-04-17 Pharmacia Spa Peptide antagonists of cellular mitogenesis and motogenesis and their therapeutic use
US5726027A (en) * 1996-03-08 1998-03-10 The Regents Of The University Of California Method for treatment of insulin resistance
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US6043247A (en) * 1996-04-19 2000-03-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
AU2807197A (en) * 1996-05-16 1997-12-05 Warner-Lambert Company Compounds inhibiting the association of the pdgf receptor and phosphatidylinositol 3-kinase and their use
US6410585B1 (en) * 1997-08-28 2002-06-25 Scott D. Larsen Inhibitors of protein tyrosine phosphatase
US6169087B1 (en) * 1997-09-23 2001-01-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
US6225329B1 (en) * 1998-03-12 2001-05-01 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US5919813C1 (en) * 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
US6166069A (en) * 1998-05-12 2000-12-26 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6451827B2 (en) * 1998-05-12 2002-09-17 Wyeth 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
WO1999061410A1 (en) * 1998-05-12 1999-12-02 American Home Products Corporation 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
US6174874B1 (en) * 1998-09-21 2001-01-16 Merck Frosst Canada & Co. Phosphonic acids derivatives as inhibitors of protein tyrosine phosphate 1B (PTP-1B)
CA2372116A1 (en) * 1999-05-14 2000-11-23 Claude Dufresne Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1b (ptp-1b)
US6410556B1 (en) * 1999-09-10 2002-06-25 Novo Nordisk A/S Modulators of protein tyrosine phosphateses (PTPases)
JP2003518128A (en) * 1999-12-22 2003-06-03 メルク フロスト カナダ アンド カンパニー Aromatic phosphonates as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
WO2001046205A1 (en) * 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
AU2335701A (en) * 1999-12-22 2001-07-03 Merck Frosst Canada & Co. Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
AU2336001A (en) * 1999-12-22 2001-07-03 Merck Frosst Canada & Co. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
US6602857B1 (en) * 2000-01-18 2003-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US6261840B1 (en) * 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
EP1134819B1 (en) * 2000-03-14 2007-04-25 Sanyo Electric Co., Ltd. Nonaqueous electrolyte secondary cells
US6465444B2 (en) * 2000-03-22 2002-10-15 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
AU7818801A (en) * 2000-07-06 2002-01-21 Array Biopharma Inc Preparation of phosphatase inhibitors
US6613903B2 (en) * 2000-07-07 2003-09-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
US6627767B2 (en) * 2000-08-29 2003-09-30 Abbott Laboratories Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
DE10059423A1 (en) * 2000-11-30 2002-06-13 Bosch Gmbh Robert Device for conveying liquids, in particular fuel
US20040002479A1 (en) * 2002-03-12 2004-01-01 Yihan Wang Peptide analogues and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008600A1 (en) * 1992-10-09 1994-04-28 Joslin Diabetes Center Inhibition of signal transduction molecules
WO2003093498A1 (en) * 2002-04-29 2003-11-13 The Ohio State University Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BURKE T R ET AL: "PHOSPHOTYROSYL-BASED MOTIFS IN THE STRUCTURE-BASED DESIGN OF PROTEIN-TYROSINE PHOSPHATASE INHIBITORS", AMERICAN CHEMICAL SOCIETY. ABSTRACTS OF PAPER. AT THE NATIONAL MEETING, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 219, 2000, pages MEDI27, XP001002165, ISSN: 0065-7727 *
BURKE T R JR ET AL: "Small molecule interactions with protein-tyrosine phosphatase PTP1B and their use in inhibitor design.", BIOCHEMISTRY. 17 DEC 1996, vol. 35, no. 50, 17 December 1996 (1996-12-17), pages 15989 - 15996, XP002369289, ISSN: 0006-2960 *
CHEN L ET AL: "Why is phosphonodifluoromethyl phenylalanine a more potent inhibitory moiety than phosphonomethyl phenylalanine toward protein-tyrosine phosphatases?", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 22 NOV 1995, vol. 216, no. 3, 22 November 1995 (1995-11-22), pages 976 - 984, XP002348262, ISSN: 0006-291X *
See also references of WO03041729A1 *
YAO Z-J ET AL: "STRUCTURE-BASED DESIGN AND SYNTHESIS OF SMALL MOLECULE PROTEIN- TYROSINE PHOSPHATASE 1B INHIBITORS", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 6, no. 10, 1998, pages 1799 - 1810, XP000863076, ISSN: 0968-0896 *
ZHANG Z Y ET AL: "Protein tyrosine phosphatase substrate specificity: size and phosphotyrosine positioning requirements in peptide substrates.", BIOCHEMISTRY. 1 MAR 1994, vol. 33, no. 8, 1 March 1994 (1994-03-01), pages 2285 - 2290, XP002348263, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
US20040191926A1 (en) 2004-09-30
JP2005509008A (en) 2005-04-07
AU2002363632B2 (en) 2007-05-24
EP1435989A1 (en) 2004-07-14
WO2003041729A1 (en) 2003-05-22
CA2461481A1 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
EP1435989A4 (en) Ptp1b inhibitors and ligands
EP1423120A4 (en) 2h-phthalazin-1-ones and methods for use thereof
AU2002240751A8 (en) Targeted ligands
GB0125445D0 (en) Protease Inhibitors
IL211772A0 (en) Apo-2 ligand variants and uses thereof
PL369855A1 (en) 4-arylquinazolines and use thereof as nhe-3 inhibitors
GB2376310B (en) Arithmetic pipeline
EP1434772A4 (en) Compounds and methods
GB0114014D0 (en) Compostion and use
IL154553A0 (en) Urocortin-iii and uses thereof
IL160620A0 (en) Combinations comprising cox-2 inhibitors and aspirin
AU2002359694A8 (en) Compounds and methods
PL367236A1 (en) Refrigerating device and refrigeratory therefor
EP1401453A4 (en) Protease inhibitors
IL153276A0 (en) Metalloprotease peptide substrates and methods
EP1379240A4 (en) Compounds and methods
EP1364653A4 (en) Casoase 3 inhibitors
GB0120009D0 (en) Cause and effect diagnosis
EP1367123A4 (en) Neurotonin and use thereof
GB0109278D0 (en) Enzyme inhibitors
GB0119955D0 (en) Ligands and their use
GB0101462D0 (en) Ligands and their use
GB0101135D0 (en) Inhibitors
GB0128453D0 (en) Inhibitors
AU2002219410A1 (en) Ligands and their use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040419

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060321

17Q First examination report despatched

Effective date: 20060803

17Q First examination report despatched

Effective date: 20060803

17Q First examination report despatched

Effective date: 20060803

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 1/06 20060101ALN20080508BHEP

Ipc: C07C 235/00 20060101ALI20080508BHEP

Ipc: C07C 233/00 20060101ALI20080508BHEP

Ipc: G01N 33/573 20060101ALI20080508BHEP

Ipc: G01N 33/53 20060101ALI20080508BHEP

Ipc: C07K 16/00 20060101ALI20080508BHEP

Ipc: C07K 1/00 20060101ALI20080508BHEP

Ipc: A61K 38/00 20060101AFI20080508BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080401